17784-60-0

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
4-(1H-Pyrazol-3-yl)pyridine is utilized as a key intermediate in the synthesis of various pharmaceutical and agrochemical products. Its unique structure allows it to be incorporated into the design of new drugs and pesticides, enhancing their efficacy and selectivity.
Used in Organic Electronics:
4-(1H-Pyrazol-3-yl)pyridine is employed as a building block for conducting materials in the field of organic electronics. Its electronic properties make it a promising candidate for use in organic light-emitting diodes (OLEDs), organic solar cells, and other electronic devices.
Used in Medicinal Chemistry Research:
4-(1H-Pyrazol-3-yl)pyridine is studied for its potential antitumor and antibacterial properties. Its ability to modulate biological processes and target specific pathways makes it a subject of interest for the development of novel therapeutic agents.
Overall, 4-(1H-Pyrazol-3-yl)pyridine demonstrates versatile applications in different industries, including pharmaceuticals, agrochemicals, and materials science. Its potential for further exploration and development highlights its significance in the advancement of various fields.

InChI:InChI=1/C8H7N3/c1-4-9-5-2-7(1)8-3-6-10-11-8/h1-6H,(H,10,11)

Upstream product

• 123367-27-1 3-(dimethylamino)-1-(pyridin-4-yl)prop-2-en-1-one 
• 123367-27-1 (E)-3-(dimethylamino)-1-(pyridin-4-yl)prop-2-en-1-one 
• 20007-63-0 5-methyl-3-(4-pyridyl)-1H-pyrazole 
• 1122-54-9 methyl (4-pyridyl) ketone 
• 109-94-4 formic acid ethyl ester 
• 68-12-2 N,N-dimethyl-formamide 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 

Downstream Products

• 690261-99-5 1-benzyl-4-(1H-pyrazol-3-yl)-1,2,3,6-tetrahydropyridine 
• 401522-11-0 2-(3-(pyridin-4-yl)-1H-pyrazol-1-yl)ethanol 
• 875414-11-2 [2-bromo-4-(3-pyridin-4-yl-pyrazol-1-yl)-phenyl]-(5,11-dihydro-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)-methanone 
• 166196-54-9 4-(4-bromo-1H-pyrazol-3-yl)pyridine 
• 1400221-06-8 N-[3-(1-ethyl-3-pyridin-4-yl-1H-pyrazol-4-yl)-phenyl]-hydroxylamine 
• 1400221-08-0 C₁₆H₁₄N₄O₂ 
• 1283092-22-7 4-(4-bromo-1-phenyl-1H-pyrazol-3-yl)pyridine 
• 1314258-26-8 3-[1-phenyl-3-(pyridin-4-yl)-1H-pyrazol-4-yl]benzoic acid 
• 1616091-43-0 1,3,5-tris(3-(pyridin-4-yl)-1H-pyrazol-1-yl)benzene 
• 690262-01-2 1-benzyl-4-(1H-pyrazol-3-yl)-piperidine 
• 1314264-02-2 4-(1-phenyl-1H-pyrazol-3-yl)-pyridine 
• 401522-15-4 C₆₀H₈₆N₄O₁₆S 

Relevant academic research and scientific papers

Finely Resolved Threshold for the Sharp M12L24/M24L48 Structural Switch in Multi-Component MnL2n Polyhedral Assemblies: X-ray, MS, NMR, and Ultracentrifugation Analyses

In the self-assembly of MnL2n polyhedra, the bend angle (θ) of the divalent ligand components determines the final structure. The threshold for the sharp structural switch between M12L24 and M24L48 was finely resolved to within just 4 by demonstrating the exclusive formation of M12L24 cuboctahedra or M24L48 rhombicuboctahedra from two similar ligands with θ values of 130 and 134. This sharp structural switch was fully confirmed by X-ray crystallography, mass spectrometry, NMR spectroscopy, and ultracentrifugation analyses.

1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in Mycobacterium tuberculosis

Phenotypic whole cell high-throughput screening of a μ150,000 diverse set of compounds against Mycobacterium tuberculosis (Mtb) in cholesterol-containing media identified 1,3-diarylpyrazolyl-acylsulfonamide 1 as a moderately active hit. Structure-activity

Discovery of a Teraryl Oxazolidinone Compound (S)-N-((3-(3-Fluoro-4-(4-(pyridin-2-yl)-1H-pyrazol-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide Phosphate as a Novel Antimicrobial Agent with Enhanced Safety Profile and Efficacies

A series of novel teraryl oxazolidinone compounds was designed, synthesized, and evaluated for their antimicrobial activity and toxicities. The compounds with aromatic N-heterocyclic substituents at the 4-position of pyrazolyl ring showed better antibacterial activity against the tested bacteria than other compounds with different patterns of substitution. Among all potent compounds, 10f exhibited promising safety profile in MTT assays and in hERG K+ channel inhibition test. Furthermore, its phosphate was found to be highly soluble in water (47.1 mg/mL), which is beneficial for the subsequent in vivo test. In MRSA systemic infection mice models, 10f phosphate exerted significantly improved survival protection compared with linezolid. The compound also demonstrated high oral bioavailability (F = 99.1%). Moreover, from the results of in vivo toxicology experiments, 10f phosphate would be predicted to have less bone marrow suppression (Chemical Equation).

RAF KINASE INHIBITORS

Described herein are compounds, pharmaceutical compositions and methods for the inhibition of RAF kinae mediated signaling. Said compounds, pharmaceutical compositions and methods have utility in the treatment of human disease and disorders.

RAF KINASE INHIBITORS

Described herein are compounds, pharmaceutical compositions and methods for the inhibition of RAF kinae mediated signaling. Said compounds, pharmaceutical compositions and methods have utility in the treatment of human disease and disorders.

Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity

The present invention is directed to compounds of the formula I: Wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X, n and the broken lines are as defined herein which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

Potent and selective pyrazole-based inhibitors of B-Raf kinase

Herein we describe a novel pyrazole-based class of ATP competitive B-Raf inhibitors. These inhibitors exhibit both excellent cellular potency and striking B-Raf selectivity. A subset of these inhibitors has demonstrated the ability to inhibit downstream ERK phosphorylation in LOX tumors from mouse xenograft studies.

RAF INHIBITOR COMPOUNDS AND METHODS

Pyrazolyl compounds of Formulas Ia and Ib are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using pyrazolyl compounds for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

New bis-, tris- and tetrakis(pyrazolyl)borate ligands with 3-pyridyl and 4-pyridyl substituents: Synthesis and coordination chemistryt

The new ligands dihydrobis[3-(4-pyridyl)pyrazol-1-yl]borate [Bp 4ph]-, hydrotris[3-(4-pyridyl)pyrazol-1-yl]borate [Tp 4py]-, tetrakis[3-(4-pyridyl)pyrazol-l-yl]borate [Tkp 4py]-, dihydrobis[3-(3-pyridyl)pyrazol-l-yl]borate [Bp 3py]-, hydrotris[3-(3-pyridyl)pyrazol-1-yl]borate [Tp 3py]- and tetrakis[3-(3-pyridyl)pyrazol-l-yl]borate [Tkp 48]- are derivatives of the well known bis-, tris- and tetrakis-(pyrazolyl)borate cores, bearing 4-pyridyl or 3-pyridyl substituents attached to the pyrazolyl C3 positions. These pyridyl groups cannot chelate to the metal ions in the poly(pyrazolyl) cavity but are externally directed. Structural studies on a range of metal complexes show how, in many cases, coordination of these pendant pyridyl groups to the M(pyrazolyl) n core of an adjacent metal complex fragment results in formation of coordination oligomers or polymeric networks. [Tl(Bp3py)], [Tl(Bp4ph)] and [Tl(Tp4py] form one-dimensional polymeric chains via coordination of one of their pendant pyridyl units to the Tl(I) centre of an adjacent complex fragment; in contrast, in [Tl(Tp3py)] coordination of all three pendant pyridyl units to separate Tl(I) neighbours results in formation of a two-dimensional polymeric sheet. In [Tl(Tkp 3py)] and [Tl(Tkp4py)] the Tl(I) is coordinated by two or three of the four pyrazolyl arms, respectively; bridging interactions of pendant 4-pyridyl groups with adjacent Tl(I) centres result in a two-dimensional sheet forming in each case. In Ag(Tkp4py) each Ag(I) ion is coordinated by two pyrazolyl rings, and two bridging pyridyl ligands from other complex units, resulting in a one-dimensional chain consisting of pairs of cross-linked zigzag chains. In contrast to these polymeric coordination networks, the structures of [Cu(Tp4py)] and [(Tp3py)Cd(CH3CO2)] are dimers, with a pendant pyridyl residue from the first metal centre attaching to a vacant coordination site on the second, and vice versa; these dimers are stabilised by π-stacking interactions between sections of the two ligands. [Ni(Tp3py)2] is monomeric, with an octahedral coordination geometry arising from two tris(pyrazolyl)borate chelates; the array of pendant 3-pyridyl groups is involved only in intramolecular hydrogen-bonding. [(Tp 4py)Re(CO)3] is also monomeric, with & facial arrangement of three pyrazolyl ligands and three carbonyls, with the pendant 4-pyridyl groups not further coordinated. [(Tp3py)Re(CO) 3], based on the related ligand hydrotris[3-(2-pyridyl)pyrazol-1-yl] borate, has a similar fac-(CO)3(pyrazolyl)3 coordination geometry. The Royal Society of Chemistry 2005.

HETEROCYCLIC CYCLOPENTYL TETRAHYDROISOQUINOLINE AND TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present invention is directed to compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X, n and the broken lines are as defined herein which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.